MBAI · Check-Cap Ltd. Ordinary Share

Check-Cap Ltd. reported a stark financial turnaround in FY2025, swinging to net income of $4.1M from a $25.1M loss in FY2024—a 116.5% year-over-year improvement. This shift occurred despite an ongoing operating loss of $2.4M, which narrowed 90.9% from $25.9M prior year. The operating improvement reflects sharply reduced expenses after discontinuing clinical studies, stabilizing core operations at a lower burn rate. However, profitability hinges on non-operating items, underscoring that fundamental business operations remain unprofitable as the company pivots strategically.

Cash flow dynamics further illustrate this stabilization. Net cash used in operating activities dropped to just $46K from $8.0M, enabling free cash flow of -$129K after $83K in capital expenditures—unchanged from prior year. This minimal burn signals effective cost discipline amid transition, but with cash reserves critically thin, liquidity pressures persist. Investors should note that such low cash generation limits runway for growth initiatives without additional funding.

Diluted EPS of $0.66, down 84.7% from $4.30, captures the dilutive impact of increased share count from September 2025 issuances. While per-share profitability turned positive, the decline highlights equity dilution as a byproduct of financing efforts to support the balance sheet.

The pending merger with MBody AI introduces material execution risks, as outlined in management discussion. MBody AI has incurred operating losses since inception and anticipates continued expenses to grow operations, develop its platform, and expand deployments. Key vulnerabilities include third-party hardware procurement for turnkey orders, which could lead to supply chain delays, compressed margins, or inventory risks. Integration with third-party software risks deployment delays and higher costs, while dependence on customer facilities may hinder scalability and performance. Failure to manage deployments or customer expectations could spark disputes, reputational harm, or reduced demand. Even satisfied customers might delay expansions due to shifting priorities, adversely affecting revenue and results. These factors emphasize that while financial metrics show stabilization, the strategic path forward carries heightened operational and dependency risks.